Technetium (99mTc) sestamibi

Phase 1Radiopharmaceutical

Technetium (99mTc) sestamibi is one of 3 small molecule programs targeting Metastatic Endometrial Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Endometrial CarcinomaActive, not recruiting

Dense BreastsCompleted

Metastatic Endometrial CarcinomaPhase 1

Active, not recruiting

Dense BreastsPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Metastatic Endometrial Carcinoma

#DrugCompanyPhaseTrials

Ruxolitinib XR

Incyte

Phase 1

1 2

Technetium (99mTc) sestamibi

MMayo Clinic

Phase 1

1 3

Ruxolitinib Phosphate

MMayo Clinic

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Metastatic Endometrial Carcinoma

NCT03120624

Clinical

Trials by Indication[1]

Dense Breasts2 trials

Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Completed·MMayo Clinic·N/A·NCT00620373·969 enrolled

Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Completed·MMayo Clinic·N/A·NCT01925170·1,638 enrolled

Metastatic Endometrial Carcinoma1 trial

Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer

Active, not recruiting·MMayo Clinic·Phase 1·NCT03120624·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Technetium (99mTc) sestamibi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Technetium (99mTc) sestamibi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Technetium (99mTc) sestamibi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 1[1]
Company: MMayo Clinic

Technetium (99mTc) sestamibi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Dense Breasts2 trials

Metastatic Endometrial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News